



## PRESS RELEASE

### Hikma appoints Kofi Amegashie to head its sub-Saharan Africa unit

**London, 26 June 2015** – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces the appointment of Kofi Amegashie as head of its newly created sub-Saharan Africa business. Kofi will lead Hikma’s expansion into this region with the aim of replicating Hikma’s brand success in the Middle East and North Africa and establishing a strong foot hold in East, West and Francophone Africa.

Kofi is a chemical engineer by training, with more than 25 years of experience with multinational organisations, including the Chevron Corporation, the International Finance Corporation, and the Coca-Cola Company, in various commercial and strategic roles in Asia, Africa, Europe, and North America. He was most recently Managing Director – Africa, at the Johannesburg-listed pharmaceutical company, Adcock Ingram Healthcare Pty. Ltd., with responsibility for all business operations in Africa, outside of South Africa.

“Kofi brings sound consumer marketing, strategic development and general management experience and we are delighted to welcome him to the Hikma team. His appointment comes at an opportune time for Hikma, as we are looking to establish a strong presence in a number of sub-Saharan markets”, said Hikma Executive Vice Chairman and Chief Executive of MENA and Emerging Markets, Mazen Darwazah.

Kofi added, "I am very impressed by Hikma's portfolio of products and its potential to meet the demands of the sub-Saharan market. The region offers attractive growth opportunities across the varied markets, which we can capture by building profitable hub country businesses and replicating them across sub-regions. Hikma is an innovative organisation and it is a great privilege to be leading its sub-Saharan expansion drive."

Kofi is a Sloan Fellow with a Master of Science degree in Management from the London Business School and holds a Bachelor of Science degree from the School of Engineering at Exeter University in the United Kingdom. He is also a Non-Executive Director of the US-based international non-profit organisation, PATH ([www.path.org](http://www.path.org)).

-- ENDS --

#### Enquiries

##### Hikma Pharmaceuticals PLC

Susan Ringdal, VP Corporate Strategy and Investor Relations

Lucinda Henderson, Deputy Director of Investor Relations

Zeena Murad, Investor Relations Manager

+44 (0)20 7399 2760/ +44 7776 477050

+44 (0)20 7399 2765/ +44 7818 060211

+44 (0)20 7399 2768/ +44 7771 665277

##### FTI Consulting

Ben Atwell/ Matthew Cole

+44 (0)20 3727 1000

**About Hikma**

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: "Injectables", "Branded" and "Generics", based principally in the United States, the Middle East and North Africa ("MENA") and Europe. In 2014, Hikma achieved revenues of \$1,489 million and profit attributable to shareholders of \$299 million.